The nation of Zimbabwe has rejected a major American health deal valued at 367 million US dollars (£272m) spanning five years because of Washington's demand for confidential information.
This move came to light after a official document from December was leaked, indicating that President Emmerson Mnangagwa deemed the deal was "skewed".
A government representative has since explained that the United States was demanding access to genetic material for research and profit but was not willing to guarantee the resulting advantages from any future vaccines.
"We will now turn to the challenging and unfortunate task of ending our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had provided over $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for continued dialogue to secure a agreement acceptable to all parties so the country's critical HIV programme can proceed.
Wider Background
Zimbabwe's decision follows a similar case in Kenya, where a court halted a similar deal with the US after legal challenges were raised about the safety of Kenyans' medical information.
Since resuming the presidency last year, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
The agency had overseen aid for the American government, but Trump claimed its expenditure was "wasteful" and his government was pursuing direct bilateral agreements to enhance openness and accountability.
According to statements, 16 African countries have to date agreed to similar agreements, constituting more than $18.3bn of fresh investment.
Specifics of the Rejected Deal
The money for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this collaboration might have yielded immense benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently on HIV treatment via US-supported programmes," the Ambassador added.
However, official spokesman Nick Mangwana argued the proposed deal was "unequal".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, with no equivalent assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that could result from that provided information," he stated.
"Effectively, our country would provide the raw materials for medical research without any assurance that the resulting innovations would be accessible to our people if a new disease outbreak emerge."
Sovereignty and International Frameworks
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were upending structures already set up via the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing system created to manage future global health emergencies.
"This mechanism is designed to guarantee that when a country contributes its information, the resulting advantages – such as medicines and cures – are distributed fairly, not commercialised solely by those with the resources to develop them."
The government's concerns over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We are open to further discussions with our US partners on how future co-operation might be arranged in a manner that respects the sovereignty and dignity of each country."
Medical Community Response
Medical experts said it understood the government's concerns, but urged that negotiations need to persist since much of the country's Aids initiatives relied on foreign aid.
"Where technical issues exist, including those relating to information security or agreement terms, these can often be addressed through detailed discussion and negotiated safeguards," it commented.
The situation underscores the continuing debate between receiving crucial foreign assistance and protecting local interests in an increasingly data-driven world.